For example, Pourhassan did the right thing by asking the FDA if it was worthwhile to file a mild/moderate EUA. The FDA said no. OK, no problem if the FDA says no, then the answer is no and that's it. But the FDA's "no" must be communicated to shareholders in a manner that doesn't get them all thinking that he is lying. Its just too much chaos for Pourhassan.